Neuropeptide Y Y5 receptor antagonists

Details Neuropeptide Y Y5 receptor antagonists Neuropeptide Y Y5 receptor antagonists

2007-01-02

2007-01-02

Saeed, Kamal A. (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C546S211000

Reexamination Certificate

active

10609638

ABSTRACT:
The present invention discloses compounds which, are receptor antagonists for NPY Y5 as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such NPY Y5 receptor antagonists as well as methods of using them to treat obesity, metabolic disorders, eating disorders such as hyperphagia, and diabetes.

REFERENCES:
patent: 4405644 (1983-09-01), Kabbe et al.
patent: 4532248 (1985-07-01), Franckowiak et al.
patent: 4616014 (1986-10-01), Teraji et al.
patent: 4623662 (1986-11-01), De Vries
patent: 4766213 (1988-08-01), Juraszyk et al.
patent: 4895841 (1990-01-01), Sugimoto et al.
patent: 5225414 (1993-07-01), Henning et al.
patent: 2005/0049237 (2005-03-01), Atkinson et al.
patent: 0945439 (1999-09-01), None
patent: 0955923 (1999-11-01), None
patent: 2216890 (1989-10-01), None
patent: 08041006 (1996-02-01), None
patent: WO 8909212 (1989-10-01), None
patent: WO 9009801 (1990-09-01), None
patent: WO 96/16542 (1996-06-01), None
patent: WO 9730045 (1997-08-01), None
patent: WO 9853814 (1998-12-01), None
patent: WO 00/27845 (2000-05-01), None
patent: WO 0069849 (2000-11-01), None
patent: WO 0249648 (2002-06-01), None
patent: WO 03037274 (2003-05-01), None
Chang, L et al. Substituted Imidazoles as Glucagon Receptor Antagonist, Bioorg. and Med. Chem. Letters, 2001, 11, pp. 2549-2553.
International Search Report for PCT/US 03/20489 (CN01595K), dated Jun. 3, 2003—5 Pages.
Stanley, et al. “Neuropeptide Y injected in the paraventicular hypothalamus: A powerful stimulant of feeding behavior”Proc. Natl. Acad. Sci.82:3940-3943(1985).
Billington, et al. “Effects of intracerebroventricular injection of neuropeptide Y on energy metabolism”Am. J. Physiol.260:R321-R327 (1991).
Wahlestedt, et al. “Neuropeptide Y-related peptides and their receptors—are the receptors potential therapeutic drug targets?”Annu. Rev. Pharmacol. Toxicol.32:309-352(1993).
Gerald, et al. “A receptor subtype involved in neuropeptide-Y-induced food intake”Nature382:168-171 (1996).
Gehlert, D., “Minireview—Multiple Receptors for the Pancreatic Polypeptide (PP-Fold) Family: Physiological Implications”Proc. Soc. Exp. Biol. Med.218:7-22(1998).
Michel, et al., “XVI. International Union of Pharmacology Recommendations for the Nomenclature of Neuropeptide Y, Peptide YY, and Pancreatic Polypeptide Receptors”Pharmacol. Rev.50(1):143-150(1998).
Hwa, et al. “Activation of the NPY Y5 receptor regulates both feeding and energy expenditure”American J. Physiological277(46):R1428-R1434(1999).

Affiliated with

Also associated with

Rating

Neuropeptide Y Y5 receptor antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Neuropeptide Y Y5 receptor antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Neuropeptide Y Y5 receptor antagonists will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3790864